Manish Kohli, MD

home / authors / manish-kohli-md

Articles

Dr. Kohli on the Use of Enzalutamide and Apalutamide in mHSPC

Dr. Kohli on the Use of Enzalutamide and Apalutamide in mHSPC

Manish Kohli, MD
May 19th 2020

Manish Kohli, MD, discusses the use of enzalutamide (Xtandi) and apalutamide (Erleada) in patients with metastatic hormone-sensitive prostate cancer (mHSPC).

Read More

Dr. Kohli on the Use of Enzalutamide and Apalutamide in mHSPC

Dr. Kohli on the Use of Enzalutamide and Apalutamide in mHSPC

Manish Kohli, MD
May 18th 2020

Manish Kohli, MD, discusses the use of enzalutamide (Xtandi) and apalutamide (Erleada) in patients with metastatic hormone-sensitive prostate cancer (mHSPC).

Read More

Dr. Kohli on Drugs That Have Been Evaluated in mCRPC

Dr. Kohli on Drugs That Have Been Evaluated in mCRPC

Manish Kohli, MD
January 25th 2020

Manish Kohli, MD, discusses drugs that have been evaluated in metastatic castration-resistant prostate cancer.

Read More

Dr. Kohli on the Challenges of Molecular Classification in Prostate Cancer

Dr. Kohli on the Challenges of Molecular Classification in Prostate Cancer

Manish Kohli, MD
September 25th 2019

Manish Kohli, MD, discusses the challenges of molecular classification in prostate cancer.

Read More

Dr. Kohli Discusses Ongoing Correlative Science in Prostate Cancer

Dr. Kohli Discusses Ongoing Correlative Science in Prostate Cancer

Manish Kohli, MD
September 11th 2019

Manish Kohli, MD, vice chair, Department of Genitourinary Oncology, Moffitt Cancer Center, discusses ongoing research with correlative sciences in prostate cancer.

Read More

Dr. Kohli on Sequencing Concerns in Metastatic Hormone-Sensitive Prostate Cancer

Dr. Kohli on Sequencing Concerns in Metastatic Hormone-Sensitive Prostate Cancer

Manish Kohli, MD
September 4th 2019

Manish Kohli, MD, vice chair, Department of Genitourinary Oncology, Moffitt Cancer Center, discusses sequencing concerns in metastatic hormone-sensitive prostate cancer (mHSPC).

Read More

Latest Updated Articles

Phase 1/2 ALKOVE-1 study of NVL-655 in ALK-positive (ALK+) solid tumors
Published: October 30th 2024 | Updated: November 7th 2024
Phase 1/2 ALKOVE-1 Study of NVL-655 in ALK-positive (ALK+) Solid Tumors
Updated Efficacy and Safety From the Phase 2 PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic NSCLC (mNSCLC)
Published: October 18th 2024 | Updated: October 21st 2024
Updated Efficacy and Safety From the Phase 2 PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic NSCLC (mNSCLC)
Daratumumab + Bortezomib/Lenalidomide/Dexamethasone in Patients With Transplant-ineligible or Transplant-deferred Newly Diagnosed Multiple Myeloma: Results of the Phase 3 CEPHEUS Study
Published: October 14th 2024 | Updated: October 16th 2024
Daratumumab + Bortezomib/Lenalidomide/Dexamethasone in Patients With Transplant-ineligible or Transplant-deferred Newly Diagnosed Multiple Myeloma: Results of the Phase 3 CEPHEUS Study
Phase 1 trial of DLL3/CD3 IgG-Like T-Cell Engager BI 764532 in Patients with DLL3 Positive Tumors: Patients with LCNEC
Published: September 27th 2024 | Updated: October 9th 2024
Petosemtamab Plus Pembrolizumab vs. Pembrolizumab Alone for First-Line (1L) Treatment of Recurrent/Metastatic (R/M) PD-L1–Positive Head and Neck Squamous Cell Carcinoma (HNSCC): A Randomized, Open-Label, Phase 3 Trial
Pooled Efficacy and Safety From 2 Pivotal Phase 2 Trials of Taletrectinib in Patients With Advanced or Metastatic ROS1+ Non–Small Cell Lung Cancer
Published: September 30th 2024 | Updated: October 4th 2024
Pooled Efficacy and Safety From 2 Pivotal Phase 2 Trials of Taletrectinib in Patients With Advanced or Metastatic ROS1+ Non–Small Cell Lung Cancer
Real world evidence of treatment practices and therapeutic outcomes for newly diagnosed NSCLC patients with non-classical EGFR mutations demonstrates high unmet medical need
Published: September 27th 2024 | Updated: October 4th 2024
Real World Evidence of Treatment Practices and Therapeutic Outcomes for Newly Diagnosed NSCLC Patients With Non-Classical EGFR Mutations Demonstrates High Unmet Medical Need